- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05616520
Treatment of Complex Femoropopliteal Artery Lesions Using Drug-coated PTA Balloon
Clinical Efficacy for the Treatment of Complex Femoropopliteal Artery Lesions Using Drug-coated PTA Balloon:a Real-world Registry Study(CARPLAY-DCB Study)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Historically, symptomatic PAD was treated with surgical bypass; however endovascular treatment is now the first line treatment when medical therapy fails. Several endovascular treatment options exist including percutaneous transluminal angioplasty (PTA), stenting with bare metal or drug-eluting stents (DES), cutting balloons, atherectomy, laser debulking. Moreover, drug-coated balloon(DCB)has emerged as a potential treatment option, combining acute restoration of vessel patency by balloon dilatation with long term maintenance of such patency by the anti-proliferative drug delivered by the balloon surface. Results from numerous clinical studies with paclitaxel coated balloons have been reported for the safety and efficacy for peripheral artery diseases.
Besides Medtronic IN.PACT Admiral, other DCBs approved for marketing in Chinese Mainland include Acoart (Acotec, China), Reewarm ® PTX (endovastec, China), Ultrafree (ZYLOX, China). Although DCBs had been widely applicable after registration, there are still lack of clinical data and evidence in the real world condition of Chinese population. Therefore, the data collection can also further expand and understand the experience of using DCB in a real world patient population in China, especially for the surveillance of safety events, in order to ensure the long-term application safety in Chinese population. Moreover, this data collection aims to perform regularly clinical follow up to guide the standardized diagnosis and treatment of patients post-operatively, in order to achieve the maximum clinical benefits of these patients, as well as improve the development of the field of peripheral artery disease treated by drug-coated balloon.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Lianrui Guo, MD.
- Phone Number: 86-13671009746
- Email: guolianrui@xwhosp.org
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100053
- Recruiting
- Xuanwu Hospital, Capital Medical University
-
Contact:
- Liqiang Li, MD
- Phone Number: 18618286609
- Email: liliqiang@xwhosp.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Rutherford grade 2-5.
- Femoropopliteal artery disease (stenosis > 50%) with at least one of following complex lesion characteristics: - long lesion (>150 mm), CTO(>50 mm),in-stent restenosis(Tosaka Ⅱ、Ⅲ), calcified lesion (PACCS grade 2-4)
- Patients who understand the purpose of this study, volunteer to participate in the experiment, sign informed consent and are willing to follow up.
- The guidewire needs to pass through the lesion.
- Life expectancy> 24 months.
- Patients who received DCB intervention after thrombus removal through PMT or CDT.
- Patients who have received DCB intervention for both lower limbs can be enrolled in the group according to the intracavitary treatment time.
- There is at least one continuous below-the-knee outflow artery or obtained by endovascular reconstruction.
- For patients combined aortic iliac artery disease, the inflow can be recanalized after endovascular reconstruction without illiac residual stenosis exceeding 50%.
Exclusion Criteria:
- Patients with stroke, cerebral hemorrhage, gastrointestinal hemorrhage or myocardial infarction within 3 months before enrollment.
- Patients who are known to be allergic to heparin, aspirin, other antiplatelet drugs, contrast agents, etc.
- Patients who have participated in clinical trials of drugs or other medical devices that interfere with this clinical trial within the past 3 months.
- Pregnant and lactating women.
- Patients who are unable or unwilling to participate in this trial.
- Patients with Buerger's disease.
- Patients who have undergone arterial bypass on the treatment side.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Freedom from clinically-driven target lesion revascularization(CD-TLR)
Time Frame: 24 months
|
Primary patency is defined as freedom from clinically driven TLR and freedom from restenosis as determined by duplex ultrasound (DUS) Peak Systolic Velocity Ratio (PSVR) ≤ 2.4
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Technical success rate
Time Frame: 1 week
|
Successfully revascularize the target vessel.
The residual stenosis is <30% and there is no acute thrombosis occurred in the target vessel within 1 week post-operation.
|
1 week
|
Primary patency
Time Frame: 1 month, 3 months, 6 months, 12 months, 24 months
|
Primary patency is defined as freedom from clinically driven TLR and freedom from restenosis as determined by duplex ultrasound (DUS) Peak Systolic Velocity Ratio (PSVR) ≤ 2.4
|
1 month, 3 months, 6 months, 12 months, 24 months
|
Freedom from clinically-driven target lesion revascularization(CD-TLR)
Time Frame: 1 month, 3 months, 6 months, 12 months, 24 months
|
Clinically-driven target lesion revascularization (CD-TLR) is defined as any re-intervention within the target lesion due to symptoms or drop of ankle brachial index (ABI) of ≥20% or >0.15 when compared to post-procedure baseline.
|
1 month, 3 months, 6 months, 12 months, 24 months
|
Major adverse events
Time Frame: 1 month, 3 months, 6 months, 12 months, 24 months
|
Operation-related acute thrombosis, arterial embolism, major amputation and all-cause mortality.
|
1 month, 3 months, 6 months, 12 months, 24 months
|
Rutherford classification change
Time Frame: 1 month, 3 months, 6 months, 12 months, 24 months
|
Rutherford classification change including ulcer healing in patients with Rutherford grade 5
|
1 month, 3 months, 6 months, 12 months, 24 months
|
improvement of EQ-5D-5L
Time Frame: 1 month, 3 months, 6 months, 12 months, 24 months
|
Improvement in the European Five Dimensional Health Scale (EQ-5D-5L) at 1 month, 3 months, 6 months, 12 months, and 24 months after surgery.
|
1 month, 3 months, 6 months, 12 months, 24 months
|
improvement of Vas-QoL
Time Frame: 1 month, 3 months, 6 months, 12 months, 24 months
|
Improvement in the quality of life scores (Vas-QoL) at 1 month, 3 months, 6 months, 12 months, 24 months after surgery.
|
1 month, 3 months, 6 months, 12 months, 24 months
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- Laird JA, Schneider PA, Jaff MR, Brodmann M, Zeller T, Metzger DC, Krishnan P, Scheinert D, Micari A, Wang H, Masters M, Tepe G. Long-Term Clinical Effectiveness of a Drug-Coated Balloon for the Treatment of Femoropopliteal Lesions. Circ Cardiovasc Interv. 2019 Jun;12(6):e007702. doi: 10.1161/CIRCINTERVENTIONS.118.007702. Epub 2019 Jun 14.
- Soga Y, Iida O, Fujihara M, Kawasaki D, Saito S, Urasawa K, Yokoi H, Fernandez EJ, Guo J, Nakamura M; IN.PACT Japan Post-Market Surveillance Study. Real-World Clinical Outcomes of IN.PACT Admiral Drug-Coated Balloon for Femoropopliteal Artery Disease - 12-Month Results From Japan Post-Market Surveillance Study. Circ J. 2021 Nov 25;85(12):2149-2156. doi: 10.1253/circj.CJ-21-0491. Epub 2021 Oct 6.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CARPLAY-DCB Study
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peripheral Arterial Disease
-
University of NebraskaNot yet recruitingPeripheral Arterial Disease | Peripheral Vascular Diseases | Peripheral Arterial Occlusive Disease | Peripheral Artery DiseaseUnited States
-
CID S.p.A.Meditrial Europe Ltd.Not yet recruitingPeripheral Arterial Occlusive Disease | Peripheral Artery DiseaseItaly
-
Marissa JarosinskiRecruitingPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Clopidogrel, Poor Metabolism of | Artery DiseaseUnited States
-
Stanford UniversityTerminatedPAD - Peripheral Arterial Disease | PVD- Peripheral Vascular DiseaseUnited States
-
Vascuros Medical Pte LtdNovella ClinicalUnknownPeripheral Arterial Occlusive Disease | Peripheral Vascular Disease | Peripheral Artery DiseaseSingapore, Belgium, Germany
-
Western Vascular Institute, IrelandRecruitingPeripheral Arterial Occlusive DiseaseIreland
-
Jena University HospitalAngioDroid s.r.l., Bologna (Italy)CompletedPeripheral Arterial Occlusive DiseaseGermany
-
Seoul National University HospitalAstellas Pharma Korea, Inc.CompletedPeripheral Arterial Occlusive DiseaseKorea, Republic of
-
Heidelberg UniversityTerminatedPeripheral Arterial Occlusive DiseaseGermany
-
Johann Wolfgang Goethe University HospitalSuspendedPeripheral Arterial Occlusive DiseaseGermany
Clinical Trials on drug-coated balloon
-
Seung-Whan Lee, M.D., Ph.D.Active, not recruitingCatheterization, Peripheral | Popliteal Artery | Angioplasty, Balloon | Femoral ArteryKorea, Republic of
-
Cantonal Hospital of St. GallenUnknownRenal InsufficiencySwitzerland
-
Xuanwu Hospital, BeijingUnknownAtherosclerosis of Artery | In-stent Arterial RestenosisChina
-
Ettore Sansavini Health Science FoundationUnknown
-
Assiut UniversityNot yet recruitingDrug Coated Balloon
-
Ulsan Medical CenterRecruitingDrug-coated BalloonKorea, Republic of
-
Nanjing First Hospital, Nanjing Medical UniversityNot yet recruiting
-
Liyuan Hospital of Tongji Medical College, Huazhong...First People's Hospital of Hangzhou; RenJi Hospital; Chengdu University of Traditional... and other collaboratorsActive, not recruitingDrug-coated Balloon | Angioplasty | Femoropopliteal Artery OcclusionChina
-
W.L.Gore & AssociatesCompleted